Episodes
-
In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable hereditary diseases and even tackle major pandemics. However, whether the answer is cell or gene therapies or RNA vaccines, one thing they all have in common is that they require DNA in some form or another as the starting material. Through Touchlight, Johnny Ohlson and his talented team have built a business that can make DNA at unprecedented speed, scale and purity. Johnny, a serial entrepreneur not originally from a biopharma background, shares with us his story of breaking successfully into a complex industry. This podcast demonstrates that innovation at its heart is more about a combination of vision, relationships and talented people rather than prior experience.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Ergomed founder Dr. Miroslav Reljanović talks to Mike Ward about how the COVID-19 pandemic has nudged clinical trials towards greater efficiency and inclusivity – and what’s needed to make good on this promising trend.
Hosted on Acast. See acast.com/privacy for more information.
-
Missing episodes?
-
In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Grace Lomax, Clinical Director at Patient Connect, a part of Clarivate. Grace’s experience as a physician highlighted numerous unmet needs beyond just clinical issues – especially around healthcare literacy, education at the point of care, adherence and more. She discusses how Patient Connect uses technology and communication strategies to inform and support patients at the point of care, and shares examples of campaigns that improved outcomes in cancer, hypertension, rare disease and asthma.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Matthew Arnold, Principal Analyst at Clarivate speaks with Dr. Kenton Johnston, Associate Professor of Health Management and Policy at Saint Louis University about disparities in the US health system. Matthew and Ken discuss both the historical context as well as the evolution of the system since the establishment of the Affordable Care Act, and how the entire spectrum of the healthcare system can work to address social determinants of health. Learn more in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward speaks with Naveed Saddiqi, Senior Partner at Novo Ventures, one of the largest venture capital groups in the life sciences sector. Naveed shares about the firm’s mandate to generate funds for the Novo Nordisk Foundation, how the pandemic impacted their investment strategy and what excites him most in the life sciences industry. Learn more in the full episode, which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021).
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Tim Guilliams, the co-founder and CEO of Healx. Healx is an artificial intelligence-powered technology company that's dedicated to helping rare disease patients access life improving treatments. Mike and Tim discuss the company’s innovative approach to drug discovery, choosing which rare diseases to target and how patients are shaping their priorities. Learn more in the full episode, which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021).
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward speaks with Richard Erwin, general manager and managing director of Roche Products Limited (UK), which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021). Richard shares how the pandemic has shifted Roche’s priorities and why the organization has heavily increased their investment in R&D. Learn more in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward speaks with Oriol Serra, former Head of Site Intelligence and Selection at Pfizer and Simon Andrews, Vice President of RWD Engagements and Innovations at Clarivate about optimizing patient-first clinical trial design and ensuring trial groups align to real-life populations and needs.
The group discusses the ins and outs to bring clinical trial management in-house, how to modernize trial designs with emerging data and intelligence, overcoming key challenges and advice for other pharma and biotechs looking to go down this path. Learn more in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward speaks with Carolyn Hynes, Director of Regulatory Intelligence at AstraZeneca, and Céline Rodier, Senior Health Policy Manager at Clarivate, about strategies and tools to gather and assess regulatory intelligence, as well as KPIs and approaches to demonstrating ROI within your organization. Get actionable takeaways in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
Increased reliance on telehealth services has been one of the most significant care delivery shifts prompted by the COVID-19 pandemic. However, the pandemic has also thrown more light on the challenges of health inequity in the United States, especially among African American and Hispanic communities. We discuss these issues and potential solutions with leaders at the eHealth Initiative, Cigna and Henry Ford Health System.
Panelists include:
Wanneh Dixon, who is Director of Programs, Strategy & Development at eHealth Initiative Will M. Lopez, the National Medical Director-Virtual Care and Senior Medical Director-Behavioral Health at Cigna; and Denise White-Perkins, who is not only the Vice Chair of Academic Affairs, Associate Residency Program Director, Department of Family Medicine, and Director, Healthcare Equity Initiatives, Office of System Diversity Equity and Inclusion at Henry Ford Health System but is also Clinical Associate Professor, at Wayne State University School of Medicine, Department of Family Medicine and Public Health SciencesHosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Toby Richardson, who is Head of Business Development and Licensing; Deputy Director of Business and Innovation at The Institute of Cancer Research. Mike and Toby discuss how research collaborations between the ICR and biopharma companies help the Institute achieve its mission to make the discoveries that defeat cancer. Learn more in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Phil Clare, the Deputy Director, Research Services (Knowledge Exchange and Engagement) at the University of Oxford. Mike and Dr. Clare discuss the key role that university research plays in shaping new medicines and technologies, and what that process looks like. Learn more in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Francesco De Rubertis, a co-founder and managing partner at Medicxi, one of the most prominent financial supporters of innovative biotech activity. Francesco provides insights into how the biotech venture capital model has evolved in the past decades to an asset-centric approach, and discusses Centessa, which recently secured $250m in funding. Learn more in the full episode.
Hosted on Acast. See acast.com/privacy for more information.
-
Clarivate market experts break down the opportunities and potential threats for 2021’s Drugs to Watch – the key drugs expected to be blockbusters by 2026.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Leen Kawas, president and CEO of Athira Pharma. Dr. Kawas shares the company’s innovative approach to treating Alzheimer’s disease by developing small molecules to restore neuronal health and stop neurodegeneration. They also discuss Athira’s recent IPO following a successful series B funding round, all during the pandemic.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Caroline Loew, President and CEO from Glympse Bio. They discuss the biotech’s focus on both disease detection and response to treatment using bioengineered sensors, starting with NASH. Dr. Loew also shares career advice for moving from pharma to biotech and how she pivoted the company’s narrative during a funding round at the bottom of the pandemic-related stock market crash.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, high definition, protein biomarker profiles. Although their launch plans were disrupted by the pandemic, Bryan shares how Adarza responded to the challenge by utilizing Ziva for COVID-19 research.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Brian Culley, CEO of Lineage Cell Therapeutics. Brian and Mike discuss the company’s cell therapy program, utilizing pluripotent stem cells, initially targeting dry age-related macular degeneration, acute spinal cord injuries, and non-small cell lung cancer. Brian shares about the status of their Phase 1/2a clinical trials, and how COVID-19 has affected the company’s operations.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Jonathan Javitt, CEO of NeuroRx. Dr Javitt discusses how NeuroRx is working in collaboration with Relief Therapeutics on Aviptadil, a synthetic version of vasoactive intestinal peptide, and a potential treatment of COVID-19 related respiratory failure. Dr. Javitt shares the promising results of an open label study of the drug, and the company’s plans if trials are successful.
Hosted on Acast. See acast.com/privacy for more information.
-
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Gil Van Bokkelen, founder, chairman and CEO of Athersys Inc. They discuss the company’s clinical program that is focusing on a special class of stem cells which display very unique properties and have been obtained from healthy young consenting donors. Mike and Gil talk about how Athersys was already working on an approach to treat patients with acute respiratory distress syndrome before the pandemic emerged and the challenges they face to tackle their COVID-19 strategy. Also, Gil shares how Athersys was successful in raising nearly $58m in April and what he thinks the company needs to do to become a multibillion-dollar company.
Hosted on Acast. See acast.com/privacy for more information.
- Show more
